Replacement, reduction, and refinement of animal experiments in anticancer drug development: the contribution of 3D in vitro cancer models in the drug efficacy …

EM Tosca, D Ronchi, D Facciolo, P Magni - Biomedicines, 2023 - mdpi.com
In the last decades three-dimensional (3D) in vitro cancer models have been proposed as a
bridge between bidimensional (2D) cell cultures and in vivo animal models, the gold …

Atlas of lobular breast cancer models: challenges and strategic directions

G Sflomos, K Schipper, T Koorman, A Fitzpatrick… - Cancers, 2021 - mdpi.com
Simple Summary Invasive lobular breast cancer (ILC) is the second most common
histological subtype of invasive breast cancer, which is noted to have a unique microscopic …

Compressive stress-mediated p38 activation required for ERα+ phenotype in breast cancer

PM Munne, L Martikainen, I Räty, K Bertula… - Nature …, 2021 - nature.com
Breast cancer is now globally the most frequent cancer and leading cause of women's
death. Two thirds of breast cancers express the luminal estrogen receptor-positive (ERα+) …

Immune microenvironment dynamics of HER2 overexpressing breast cancer under dual anti-HER2 blockade

S Batalha, CM Gomes, C Brito - Frontiers in Immunology, 2023 - frontiersin.org
Introduction The clinical prognosis of the HER2-overexpressing (HER2-OE) subtype of
breast cancer (BC) is influenced by the immune infiltrate of the tumor. Specifically, monocytic …

USP36 promotes tumorigenesis and tamoxifen resistance in breast cancer by deubiquitinating and stabilizing ERα

T Zhuang, S Zhang, D Liu, Z Li, X Li, J Li… - Journal of Experimental …, 2024 - Springer
Background Breast cancer is the most prevalent cancer in women globally. Over-activated
estrogen receptor (ER) α signaling is considered the main factor in luminal breast cancers …

The peripheral immune landscape of breast cancer: clinical findings and in vitro models for biomarker discovery

S Batalha, S Ferreira, C Brito - Cancers, 2021 - mdpi.com
Simple Summary Breast cancer is a major health concern as it remains the deadliest for
women worldwide. As for other cancer types, the immune system is determinant for how the …

[HTML][HTML] How to build a tumor: An industry perspective

J Schueler, J Borenstein, L Buti, M Dong… - Drug Discovery …, 2022 - Elsevier
During the past 15 years, a plethora of innovative 3D in vitro systems has been developed.
They offer the possibility of identifying crucial cellular and molecular contributors to the …

Breast cancer prevention with liquiritigenin from licorice through the inhibition of aromatase and protein biosynthesis in high-risk women's breast tissue

A Hajirahimkhan, C Howell, ET Bartom, H Dong… - Scientific reports, 2023 - nature.com
Breast cancer risk continues to increase post menopause. Anti-estrogen therapies are
available to prevent postmenopausal breast cancer in high-risk women. However, their …

[HTML][HTML] Capturing the third dimension in drug discovery: Spatially-resolved tools for interrogation of complex 3D cell models

D Simão, CM Gomes, PM Alves, C Brito - Biotechnology Advances, 2022 - Elsevier
Abstract Advanced three-dimensional (3D) cell models have proven to be capable of
depicting architectural and microenvironmental features of several tissues. By providing data …

Exploring the Potential of PEG‐Heparin Hydrogels to Support Long‐Term Ex Vivo Culture of Patient‐Derived Breast Explant Tissues

MK Koch, A Ravichandran, B Murekatete… - Advanced …, 2023 - Wiley Online Library
Breast cancer is a complex, highly heterogenous, and dynamic disease and the leading
cause of cancer‐related death in women worldwide. Evaluation of the heterogeneity of …